Literature DB >> 8510800

Regulation of His-dTrp-Ala-Trp-dPhe-Lys-NH2 (GHRP-6)-induced GH secretion in the rat.

F Mallo1, C V Alvarez, L Benitez, B Burguera, R Coya, F F Casanueva, C Dieguez.   

Abstract

His-dTrp-Ala-Trp-dPhe,Lys-NH2(GHRP-6) is a synthetic compound that releases GH in a dose-response and specific manner in several species and that may well be related to an endogenous compound of similar structure. The aim of this study was to investigate the in vivo GH responses to GHRP-6 in pentobarbital anesthetized rats. Specifically and in order to avoid the influence of endogenous GHRH and somatostatin secretion we studied the GH responses to GHRP-6 in animals with surgical ablation of the hypothalamus, confirmed by histological assessment, as well as in hypophysectomyzed-transplanted rats bearing two hypophyses under the renal capsule. Since it has been previously reported that rats pretreated with GHRH (10 micrograms/kg i.p. every 12 h for 15 days) rather than saline-treated rats have greater GH responses to acutely administered GHRH, we compared the self-potentiating effect of chronic GH pretreatment with GHRP-6 (10 micrograms/kg i.p. every 12 h). Furthermore we also studied the influence of estrogens, glucocorticoids, free fatty acids (FFA) and bombesin on somatotroph responsiveness to GHRP-6 in intact rats. We found a greater GH response to GHRP-6 in rats that underwent a surgical ablation of the hypothalamus 36 h prior to the test than in sham-operated rats. A direct stimulatory effect of GHRP-6 on in vivo GH secretion was demonstrated by a clear GH response to GHRP-6 in hypophysectomyzed-transplanted rats. In addition, we found a similar response whether the animals were pretreated with GHRH or GHRP-6 over the previous 2 weeks. Finally, we found that both estrogen- and testosterone-treated rats have greater GH responses to GHRP-6 than untreated rats. On the other hand, chronic dexamethasone administration, acute elevation of circulating FFA levels and bombesin administration markedly inhibited GH responses to GHRP-6. In contrast to the effects exerted on GH responses to GHRP-6 estrogen administration led to a decrease in GH responses to GHRH while dexamethasone did not affect the GH responses to GHRH, highlighting a differential regulation of these hormones on somatotroph responsiveness to these peptides.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8510800     DOI: 10.1159/000126366

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  5 in total

Review 1.  Growth hormone secretagogues as diagnostic tools in disease states.

Authors:  R Baldelli; X L Otero; J P Camiña; O Gualillo; V Popovic; C Dieguez; F F Casanueva
Journal:  Endocrine       Date:  2001-02       Impact factor: 3.633

Review 2.  Interactive regulation of postmenopausal growth hormone insulin-like growth factor axis by estrogen and growth hormone-releasing peptide-2.

Authors:  J D Veldhuis; W S Evans; C Y Bowers; S Anderson
Journal:  Endocrine       Date:  2001-02       Impact factor: 3.633

3.  Tyr-Ala-Hexarelin, a synthetic octapeptide, possesses the same endocrine activities of Hexarelin and GHRP-2 in humans.

Authors:  E Arvat; L Di Vito; F Lanfranco; F Broglio; R Giordano; A Benso; G P Muccioli; R Deghenghi; E Ghigo
Journal:  J Endocrinol Invest       Date:  1999-02       Impact factor: 4.256

4.  Hexarelin, a synthetic GH-releasing peptide, is a powerful stimulus of GH secretion in pubertal children and in adults but not in prepubertal children and in elderly subjects.

Authors:  J Bellone; E Bartolotta; C Sgattoni; G Aimaretti; E Arvat; S Bellone; R Deghenghi; E Ghigo
Journal:  J Endocrinol Invest       Date:  1998-09       Impact factor: 4.256

5.  Ghrelin improves growth hormone responses to growth hormone-releasing hormone in a streptozotocin-diabetic model of delayed onset.

Authors:  Y Diz-Chaves; C Spuch; D Pérez; F Mallo
Journal:  J Endocrinol Invest       Date:  2007-04       Impact factor: 4.256

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.